Navigation Links
PreSCD II Registry Shows ICDs Lead to 44 Percent Reduction in Mortality for Heart Attack Survivors
Date:9/1/2009

NATICK, Mass. and BARCELONA, Sept. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II). The results found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality (p=0.053) when implanted in patients following myocardial infarction (heart attack). The mortality reduction trend was also observed in high-risk patients with severely reduced heart function. Analysis of the data was presented by Professor Heinz Voller, M.D., Klinikum am See, Ruedersdorf, Germany at the annual European Society of Cardiology (ESC) Congress in Barcelona.

Heart attack survivors have an increased risk for sudden cardiac death, and patients with impaired left ventricular function in particular benefit from protection by an ICD. Major clinical trials such as MADIT II suggest that ejection fraction -- a measure of the heart's pumping capacity -- should be used to characterize risk and determine which patients should receive an ICD. Data from PreSCD II revealed that within the highest risk subgroup (ejection fraction <= 30%), only 22 percent of patients were prescribed ICD therapy.

"The PreSCD II data provide real-world confirmation of the findings of randomized clinical trials that have shown ICDs reduce mortality following a heart attack," said Professor Voller. "In addition, PreSCD II confirms that actual ICD implantation rates for the highest risk subgroup were lower than those recommended by current guidelines and other study results. This is a significant concern because the mortality reduction associated with an ICD was greatest among these patients. We were also interested to observe a survival benefit that increased with the time interval between heart attack and ICD implantation."

The PreSCD II registry enrolled 10,612 heart attack survivors between 2002 and 2005 in 19 centers in Germany. It has been endorsed by the German Society of Cardiology and the German Society for Prevention and Rehabilitation.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT: Paul Donovan
             508-650-8541 (office)
             508-667-5165 (mobile)
             Media Relations
             Boston Scientific Corporation

             David Knutson
             651-260-8288 (mobile)
             Media Relations
             Boston Scientific Corporation

             Larry Neumann
             508-650-8696 (office)
             Investor Relations
             Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Help Save a Life - Bone Marrow Donor Registry Drive Sept. 2 at the Karmanos Cancer Center
2. CAS REGISTRY(SM), the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
3. Featherstone Informatics Group, Inc. Named Exclusive Vendor for the American College of Cardiologys Practice-Based Data Registry Program
4. Greenway Medical Technologies EHR Solution, PrimeSuite, Enables Eligible Professionals to Participate in PQRI Through Integration With Outcome Sciences, a 2009 CMS Qualified PQRI Registry
5. Lilly Announces Continued Commitment to Transparency with Faculty Registry
6. VIDEO from Medialink and the American Academy of Orthopaedic Surgeons: American Joint Replacement Registry Announced
7. American Joint Replacement Registry Announced
8. New national adolescent weight control registry will recognize successful teen weight loss efforts
9. Social Security Institute Launches the National Obamacare Opt Out (NOOO!) Registry
10. Reportable Food Registry Draft Guidance Published for Comment by FDA
11. Meridios, Ltd Selected as a Nationwide CMS Qualified Registry to Report Healthcare Quality Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology: